Abstract
The human cytomegalovirus (HCMV) is a common pathogen, which causes severe or even deadly diseases in immunocompromised patients. In addition, congenital HCMV infection represents a major health concern affecting especially the lung tissue of the susceptible individuals. Antivirals are a useful strategy to treat HCMV-caused diseases. However, all approved drugs target viral proteins but significant toxicity and an increasing resistance against these compounds have been observed. In infected cells, numerous host molecules have been identified to play important roles during HCMV replication. Among others, HCMV infection depends on the presence of bioactive sphingolipids. In this study, the role of sphingosine-1-phosphate (S1P) signaling in HCMV-infected human embryonal lung fibroblasts (HELF) was analyzed. Viral replication depended on the functional activity of sphingosine kinases (SK). During SK inhibition, addition of extracellular S1P restored HCMV replication. Moreover, neutralization of extracellular S1P by anti-S1P antibodies decreased HCMV replication as well. While the application of FTY720 as an functional antagonist of S1P receptor (S1PR)1,3−5 signaling did not reduce HCMV replication significantly, JTE-013, an inhibitor of S1PR2, decreased viral replication. Furthermore, inhibition of Rac-1 activity reduced HCMV replication, whereas inhibition of the Rac-1 effector protein Rac-1-activated kinase 1 (PAK1) had no influence. In general, targeting S1P-induced pathways, which are essential for a successful HCMV replication, may represent a valuable strategy to develop new antiviral drugs.
Similar content being viewed by others
References
Fishman JA (2017) Infection in organ transplantation. Am J Transpl 17(4):856–879
Selvey LA, Lim WH, Boan P, Swaminathan R, Slimings C, Harrison AE, Chakera A (2017) Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience. BMC Infect Dis 17(1):501
de Maar EF, Verschuuren EA, Harmsen MC, The TH, van Son WJ (2003) Pulmonary involvement during cytomegalovirus infection in immunosuppressed patients. Transpl Infect Dis 5(3):112–120
Travi G, Pergam SA (2014) Cytomegalovirus pneumonia in hematopoietic stem cell recipients. J Intensive Care Med 29(4):200–212
Ison MG, Fishman JA (2005) Cytomegalovirus pneumonia in transplant recipients. Clin Chest Med 26(4):691–705 viii.
Murph JR, Souza IE, Dawson JD, Benson P, Petheram SJ, Pfab D, Gregg A, O’Neill ME, Zimmerman B, Bale JF Jr (1998) Epidemiology of congenital cytomegalovirus infection: maternal risk factors and molecular analysis of cytomegalovirus strains. Am J Epidemiol 147(10):940–947
Cannon MJ (2009) Congenital cytomegalovirus (CMV) epidemiology and awareness. J Clin Virol 46(4):S6–10
Bissinger AL, Sinzger C, Kaiserling E, Jahn G (2002) Human cytomegalovirus as a direct pathogen: correlation of multiorgan involvement and cell distribution with clinical and pathological findings in a case of congenital inclusion disease. J Med Virol 67(2):200–206
Gabrielli L, Bonasoni MP, Lazzarotto T, Lega S, Santini D, Foschini MP, Guerra B, Baccolini F, Piccirilli G, Chiereghin A, Petrisli E, Gardini G, Lanari M, Landini MP (2009) Histological findings in foetuses congenitally infected by cytomegalovirus. J Clin Virol 46(Suppl 4):S16–21
Dulal K, Cheng T, Yang L, Wang W, Huang Y, Silver B, Selariu A, Xie C, Wang D, Espeseth A, Lin Y, Wen L, Xia N, Fu TM, Zhu H (2016) Functional analysis of human cytomegalovirus UL/b’ region using SCID-hu mouse model. J Med Virol 88(8):1417–1426
Maidji E, Kosikova G, Joshi P, Stoddart CA (2012) Impaired surfactant production by alveolar epithelial cells in a SCID-hu lung mouse model of congenital human cytomegalovirus infection. J Virol 86(23):12795–12805
Balthesen M, Messerle M, Reddehase MJ (1993) Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol 67(9):5360–5366
Reddehase MJ, Weiland F, Munch K, Jonjic S, Luske A, Koszinowski UH (1985) Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol 55(2):264–273
Podlech J, Holtappels R, Pahl-Seibert MF, Steffens HP, Reddehase MJ (2000) Murine model of interstitial cytomegalovirus pneumonia in syngeneic bone marrow transplantation: persistence of protective pulmonary CD8-T-cell infiltrates after clearance of acute infection. J Virol 74(16):7496–7507
Sinzger C, Grefte A, Plachter B, Gouw AS, The TH, Jahn G (1995) Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. J Gen Virol 76(Pt 4):741–750
Sinzger C, Digel M, Jahn G (2008) Cytomegalovirus cell tropism. Curr Top Microbiol Immunol 325:63–83
Timpone JG, Yimen M, Cox S, Teran R, Ajluni S, Goldstein D, Fishbein T, Kumar PN, Matsumoto C (2016) Resistant cytomegalovirus in intestinal and multivisceral transplant recipients. Transpl Infect Dis 18(2):202–209
El Chaer F, Shah DP, Chemaly RF (2016) How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood 128(23):2624–2636
Hanson KE, Swaminathan S (2015) Cytomegalovirus antiviral drug resistance: future prospects for prevention, detection and management. Future Microbiol 10(10):1545–1548
Kagele D, Rossetto CC, Tarrant MT, Pari GS (2012) Analysis of the interactions of viral and cellular factors with human cytomegalovirus lytic origin of replication, oriLyt. Virology 424(2):106–114
Munger J, Bajad SU, Coller HA, Shenk T, Rabinowitz JD (2006) Dynamics of the cellular metabolome during human cytomegalovirus infection. PLoS Pathog 2(12):e132
Munger J, Bennett BD, Parikh A, Feng XJ, McArdle J, Rabitz HA, Shenk T, Rabinowitz JD (2008) Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nat Biotechnol 26(10):1179–1186
McArdle J, Moorman NJ, Munger J (2012) HCMV targets the metabolic stress response through activation of AMPK whose activity is important for viral replication. PLoS Pathog 8(1):e1002502
Schneider-Schaulies J, Schneider-Schaulies S (2015) Sphingolipids in viral infection. Biol Chem 396(6–7):585–595
Maceyka M, Spiegel S (2014) Sphingolipid metabolites in inflammatory disease. Nature 510(7503):58–67
Thuy AV, Reimann CM, Hemdan NY, Graler MH (2014) Sphingosine 1-phosphate in blood: function, metabolism, and fate. Cell Physiol Biochem 34(1):158–171
Maceyka M, Payne SG, Milstien S, Spiegel S (2002) Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta 1585(2–3):193–201
Proia RL, Hla T (2015) Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest 125(4):1379–1387
Rodriguez YI, Campos LE, Castro MG, Aladhami A, Oskeritzian CA, Alvarez SE (2016) Sphingosine-1 phosphate: a new modulator of immune plasticity in the tumor microenvironment. Front Oncol 6:218
Machesky NJ, Zhang G, Raghavan B, Zimmerman P, Kelly SL, Merrill AH Jr, Waldman WJ, Van Brocklyn JR, Trgovcich J (2008) Human cytomegalovirus regulates bioactive sphingolipids. J Biol Chem 283(38):26148–26160
Sobel K, Menyhart K, Killer N, Renault B, Bauer Y, Studer R, Steiner B, Bolli MH, Nayler O, Gatfield J (2013) Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling. J Biol Chem 288(21):14839–14851
Wang D, Shenk T (2005) Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 102(50):18153–18158
Wang D, Shenk T (2005) Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 79(16):10330–10338
Wilkinson GW, Davison AJ, Tomasec P, Fielding CA, Aicheler R, Murrell I, Seirafian S, Wang EC, Weekes M, Lehner PJ, Wilkie GS, Stanton RJ (2015) Human cytomegalovirus: taking the strain. Med Microbiol Immunol 204(3):273–284
Renzette N, Bhattacharjee B, Jensen JD, Gibson L, Kowalik TF (2011) Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. PLoS Pathog 7(5):e1001344
Renzette N, Kowalik TF, Jensen JD (2016) On the relative roles of background selection and genetic hitchhiking in shaping human cytomegalovirus genetic diversity. Mol Ecol 25(1):403–413
Kawabori M, Kacimi R, Karliner JS, Yenari MA (2013) Sphingolipids in cardiovascular and cerebrovascular systems: pathological implications and potential therapeutic targets. World J Cardiol 5(4):75–86
Ford Siltz LA, Viktorova EG, Zhang B, Kouiavskaia D, Dragunsky E, Chumakov K, Isaacs L, Belov GA (2014) New small-molecule inhibitors effectively blocking picornavirus replication. J Virol 88(19):11091–11107
Lou Z, Sun Y, Rao Z (2014) Current progress in antiviral strategies. Trends Pharmacol Sci 35(2):86–102
Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER (2001) L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 276(1):40–47
Stahmann N, Woods A, Spengler K, Heslegrave A, Bauer R, Krause S, Viollet B, Carling D, Heller R (2010) Activation of AMP-activated protein kinase by vascular endothelial growth factor mediates endothelial angiogenesis independently of nitric-oxide synthase. J Biol Chem 285(14):10638–10652
Rowe WP, Huebner RJ, Gilmore LK, Parrott RH, Ward TG (1953) Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 84(3):570–573
Stanton RJ, Baluchova K, Dargan DJ, Cunningham C, Sheehy O, Seirafian S, McSharry BP, Neale ML, Davies JA, Tomasec P, Davison AJ, Wilkinson GW (2010) Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest 120(9):3191–3208
Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, Messerle M, Hengel H, Koszinowski U, Brune W, Adler B (2008) Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J Gen Virol 89(Pt 2):359–368
Berridge MV, Herst PM, Tan AS (2005) Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11:127–152
Ammer E, Nietzsche S, Rien C, Kuhnl A, Mader T, Heller R, Sauerbrei A, Henke A (2015) The anti-obesity drug orlistat reveals anti-viral activity. Med Microbiol Immunol 204(6):635–645
Carrizzo A, Forte M, Lembo M, Formisano L, Puca AA, Vecchione C (2014) Rac-1 as a new therapeutic target in cerebro- and cardio-vascular diseases. Curr Drug Targets 15(13):1231–1246
Richerioux N, Blondeau C, Wiedemann A, Remy S, Vautherot JF, Denesvre C (2012) Rho-ROCK and Rac-PAK signaling pathways have opposing effects on the cell-to-cell spread of Marek’s Disease Virus. PLoS One 7(8):e44072
Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y (2004) Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci USA 101(20):7618–7623
Kumar R, Sanawar R, Li X, Li F (2017) Structure, biochemistry, and biology of PAK kinases. Gene 605:20–31
Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J, Peterson JR (2008) An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 15(4):322–331
Sinzger C, Jahn G (1996) Human cytomegalovirus cell tropism and pathogenesis. Intervirology 39(5–6):302–319
Melendez AJ, Carlos-Dias E, Gosink M, Allen JM, Takacs L (2000) Human sphingosine kinase: molecular cloning, functional characterization and tissue distribution. Gene 251(1):19–26
Huang RT (1976) Sphingolipids of influenza viruses. Biochim Biophys Acta 424(1):90–97
Miccheli A, Ricciolini R, Lagana A, Piccolella E, Conti F (1991) Modulation of the free sphingosine levels in Epstein Barr virus transformed human B lymphocytes by phorbol dibutyrate. Biochim Biophys Acta 1095(1):90–92
Yang TC, Lai CC, Shiu SL, Chuang PH, Tzou BC, Lin YY, Tsai FJ, Lin CW (2010) Japanese encephalitis virus down-regulates thioredoxin and induces ROS-mediated ASK1-ERK/p38 MAPK activation in human promonocyte cells. Microbes Infect 12(8–9):643–651
Qin Z, Dai L, Trillo-Tinoco J, Senkal C, Wang W, Reske T, Bonstaff K, Del Valle L, Rodriguez P, Flemington E, Voelkel-Johnson C, Smith CD, Ogretmen B, Parsons C (2014) Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Mol Cancer Ther 13(1):154–164
Yamane D, Zahoor MA, Mohamed YM, Azab W, Kato K, Tohya Y, Akashi H (2009) Inhibition of sphingosine kinase by bovine viral diarrhea virus NS3 is crucial for efficient viral replication and cytopathogenesis. J Biol Chem 284(20):13648–13659
Spiegel S, Milstien S (2003) Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4(5):397–407
Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, Spiegel S, Hla T (1998) Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 279(5356):1552–1555
Aarthi JJ, Darendeliler MA, Pushparaj PN (2011) Dissecting the role of the S1P/S1PR axis in health and disease. J Dent Res 90(7):841–854
Spiegel S, Milstien S (2011) The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 11(6):403–415
Blankenbach KV, Schwalm S, Pfeilschifter J, Meyer Zu Heringdorf D (2016) Sphingosine-1-phosphate receptor-2 antagonists: therapeutic potential and potential risks. Front Pharmacol 7:167
Tong S, Tian J, Wang H, Huang Z, Yu M, Sun L, Liu R, Liao M, Ning Z (2013) H9N2 avian influenza infection altered expression pattern of sphiogosine-1-phosphate receptor 1 in BALB/c mice. Virol J 10:296
Wang X, Yu Y, Li M, Yu Y, Liu G, Xie Y, Liu Y, Yang X, Zou Y, Ge J, Chen R (2017) Sphingosine 1-phosphate alleviates Coxsackievirus B3-induced myocarditis by increasing invariant natural killer T cells. Exp Mol Pathol 103(2):210–217
Nagahashi M, Takabe K, Terracina KP, Soma D, Hirose Y, Kobayashi T, Matsuda Y, Wakai T (2014) Sphingosine-1-phosphate transporters as targets for cancer therapy. Biomed Res Int 2014:651727
Van den Broeke C, Jacob T, Favoreel HW (2014) Rho’ing in and out of cells: viral interactions with Rho GTPase signaling. Small GTPases 5:e28318
Xiang Y, Zheng K, Ju H, Wang S, Pei Y, Ding W, Chen Z, Wang Q, Qiu X, Zhong M, Zeng F, Ren Z, Qian C, Liu G, Kitazato K, Wang Y (2012) Cofilin 1-mediated biphasic F-actin dynamics of neuronal cells affect herpes simplex virus 1 infection and replication. J Virol 86(16):8440–8451
Roberts KL, Baines JD (2011) Actin in herpesvirus infection. Viruses 3(4):336–346
Hoppe S, Schelhaas M, Jaeger V, Liebig T, Petermann P, Knebel-Morsdorf D (2006) Early herpes simplex virus type 1 infection is dependent on regulated Rac1/Cdc42 signalling in epithelial MDCKII cells. J Gen Virol 87(Pt 12):3483–3494
Petermann P, Haase I, Knebel-Morsdorf D (2009) Impact of Rac1 and Cdc42 signaling during early herpes simplex virus type 1 infection of keratinocytes. J Virol 83(19):9759–9772
Murata T, Goshima F, Daikoku T, Takakuwa H, Nishiyama Y (2000) Expression of herpes simplex virus type 2 US3 affects the Cdc42/Rac pathway and attenuates c-Jun N-terminal kinase activation. Genes Cells 5(12):1017–1027
Van den Broeke C, Radu M, Chernoff J, Favoreel HW (2010) An emerging role for p21-activated kinases (Paks) in viral infections. Trends Cell Biol 20(3):160–169
Jacob T, Van den Broeke C, van Troys M, Waterschoot D, Ampe C, Favoreel HW (2013) Alphaherpesviral US3 kinase induces cofilin dephosphorylation to reorganize the actin cytoskeleton. J Virol 87(7):4121–4126
Zheng K, Xiang Y, Wang X, Wang Q, Zhong M, Wang S, Wang X, Fan J, Kitazato K, Wang Y (2014) Epidermal growth factor receptor-PI3K signaling controls cofilin activity to facilitate herpes simplex virus 1 entry into neuronal cells. MBio 5(1):e00958–00913
Iden S, Collard JG (2008) Crosstalk between small GTPases and polarity proteins in cell polarization. Nat Rev Mol Cell Biol 9(11):846–859
Carr JM, Mahalingam S, Bonder CS, Pitson SM (2013) Sphingosine kinase 1 in viral infections. Rev Med Virol 23(2):73–84
Acknowledgements
We would like to thank Roger Sabbadini for providing the S1P-specific antibody Lpath Lt1002 as well as the non-specific control antibody Lpath Lt1013. We also thank Christian Sinzger (Institute of Virology, University of Ulm, Ulm, Germany) and Richard J. Stanton (Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK) for providing HCMV strains TB40/E and Merlin, respectively.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicting financial or other interests.
Rights and permissions
About this article
Cite this article
Zilch, A., Rien, C., Weigel, C. et al. Influence of sphingosine-1-phosphate signaling on HCMV replication in human embryonal lung fibroblasts. Med Microbiol Immunol 207, 227–242 (2018). https://doi.org/10.1007/s00430-018-0543-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00430-018-0543-4